OBJECTIVE: To assess the testicular Sertoli cell function in male SLE patients. METHODS: Thirty-four consecutive patients were prospectively selected to evaluate serum inhibin B. Clinical features, treatment, semen analysis, urological evaluation, testicular ultrasound, hormones and anti-sperm antibodies were determined. RESULTS: Patients were subdivided into two groups: low serum inhibin B (Group 1, n = 8) and normal levels (Group 2, n = 26). The median sperm concentration (P = 0.024), total sperm count (P = 0.023) and total motile sperm count (P = 0.025) were lower in Group 1. Inhibin B levels were positively correlated with sperm concentration (r = 0.343), total motile sperm count (r = 0.357), and negatively correlated with follicule-stimulating hormone (FSH) (r = 0.699) and luteinizing hormone (r = 0.397). The median serum inhibin B was lower in SLE patients treated with intravenous cyclophosphamide (IVCYC) compared with those without this therapy (P = 0.031). Further evaluation of the 26 SLE patients with normal inhibin B and FSH levels revealed that medians of inhibin B/FSH ratio were lower in SLE patients with oligozoospermia compared with normozoospermia (P = 0.004). This ratio was also lower in SLE patients treated with IVCYC than those without this therapy (P = 0.04). In contrast, inhibin B serum level alone did not discriminate the later group of patients (P = 0.12). CONCLUSIONS: This is the first study to identify a high frequency of testicular Sertoli cell dysfunction in male SLE associated with semen abnormalities. Further prospective studies are necessary to determine if inhibin levels and inhibin B/FSH ratio will be an earlier and useful marker of IVCYC toxicity in these patients.
OBJECTIVE: To assess the testicular Sertoli cell function in male SLEpatients. METHODS: Thirty-four consecutive patients were prospectively selected to evaluate serum inhibin B. Clinical features, treatment, semen analysis, urological evaluation, testicular ultrasound, hormones and anti-sperm antibodies were determined. RESULTS:Patients were subdivided into two groups: low serum inhibin B (Group 1, n = 8) and normal levels (Group 2, n = 26). The median sperm concentration (P = 0.024), total sperm count (P = 0.023) and total motile sperm count (P = 0.025) were lower in Group 1. Inhibin B levels were positively correlated with sperm concentration (r = 0.343), total motile sperm count (r = 0.357), and negatively correlated with follicule-stimulating hormone (FSH) (r = 0.699) and luteinizing hormone (r = 0.397). The median serum inhibin B was lower in SLEpatients treated with intravenous cyclophosphamide (IVCYC) compared with those without this therapy (P = 0.031). Further evaluation of the 26 SLEpatients with normal inhibin B and FSH levels revealed that medians of inhibin B/FSH ratio were lower in SLEpatients with oligozoospermia compared with normozoospermia (P = 0.004). This ratio was also lower in SLEpatients treated with IVCYC than those without this therapy (P = 0.04). In contrast, inhibin B serum level alone did not discriminate the later group of patients (P = 0.12). CONCLUSIONS: This is the first study to identify a high frequency of testicular Sertoli cell dysfunction in male SLE associated with semen abnormalities. Further prospective studies are necessary to determine if inhibin levels and inhibin B/FSH ratio will be an earlier and useful marker of IVCYC toxicity in these patients.
Authors: Luís Rato; Marco G Alves; Sílvia Socorro; Ana I Duarte; José E Cavaco; Pedro F Oliveira Journal: Nat Rev Urol Date: 2012-05-01 Impact factor: 14.432
Authors: Clovis A Silva; Maria E J Deen; Marilia V Febrônio; Sheila K Oliveira; Maria T Terreri; Silvana B Sacchetti; Flavio R Sztajnbok; Roberto Marini; Maria V Quintero; Blanca E Bica; Rosa M Pereira; Eloisa Bonfá; Virginia P Ferriani; Teresa C Robazzi; Claudia S Magalhães; Maria O Hilário Journal: Rheumatol Int Date: 2010-03-21 Impact factor: 2.631
Authors: Andrea R S Mont'Alverne; Lucas Y S Yamakami; Célio R Gonçalves; Edmund C Baracat; Eloisa Bonfá; Clovis A Silva Journal: Clin Rheumatol Date: 2014-05-31 Impact factor: 2.980
Authors: Francesca Fallarino; Giovanni Luca; Mario Calvitti; Francesca Mancuso; Claudio Nastruzzi; Maria C Fioretti; Ursula Grohmann; Ennio Becchetti; Anne Burgevin; Roland Kratzer; Peter van Endert; Louis Boon; Paolo Puccetti; Riccardo Calafiore Journal: J Exp Med Date: 2009-10-12 Impact factor: 14.307